11 completed, 7 unknown, 2 not yet recruiting, 2 terminated. 24 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 24 | Completed 11, Unknown 7, Not yet recruiting 2, Terminated 2, Withdrawn 2 |
Follow Pulmonary Fibrosis: new trials by email Literature Review of Pulmonary Fibrosis trials Research Report on Pulmonary Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD Gabapentin, Benzonatate 200 mg, Standard of care treatment for ILD - Interstitial Lung Disease | Phase 4 | Not yet recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 177 | 2026-10-07 | 2026-10-08 |
| This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination. Nerandomilast 18 mg - adult formulation - Pulmonary Fibrosis, Interstitial Lung Disease (ILD) | Phase 4 | Not yet recruiting | University of British Columbia | 120 | 2026-06-01 | 2026-05-11 |
| Colchicine and Post-COVID-19 Pulmonary Fibrosis Colchicine 0.5 MG, the standard protocol only - Covid19, Pulmonary Fibrosis Interstitial | Phase 4 | Unknown | ClinAmygate | 260 | 2021-03-25 | 2023-09-06 |
| The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19 Nintedanib, Placebo - Pulmonary Fibrosis, Interstitial Lung Disease | Phase 4 | Completed | Icahn School of Medicine at Mount Sinai | 103 | 2020-11-18 | 2026-04-30 |
| Management of Progressive Disease in Idiopathic Pulmonary Fibrosis pirfenidone and nintedanib, pirfenidone or nintedanib - Progressive Idiopathic Pulmonary Fibrosis | Phase 4 | Completed | Hospices Civils de Lyon | 279 | 2020-06-11 | 2026-02-09 |
| Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF) Nintedanib, Pulmonary rehabilitation program - Idiopathic Pulmonary Fibrosis | Phase 4 | Terminated | Boehringer Ingelheim | 19 | 2018-11-15 | 2021-06-09 |
| Digital Auscultation Test - IPF Data Collection Littmann ® - Idiopathic Pulmonary Fibrosis | Phase 4 | Completed | Boehringer Ingelheim | 274 | 2018-03-28 | 2020-01-27 |
| Pirfenidone for Progressive Fibrotic Sarcoidosis Pirfenidone, Placebos - Sarcoidosis, Pulmonary | Phase 4 | Unknown | University of Cincinnati | 60 | 2017-09-27 | 2017-09-28 |
| Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment nintedanib, placebo - Idiopathic Pulmonary Fibrosis | Phase 4 | Completed | Boehringer Ingelheim | 347 | 2016-06-09 | 2023-12-21 |
| A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination nintedanib, pirfenidone - Idiopathic Pulmonary Fibrosis | Phase 4 | Completed | Boehringer Ingelheim | 37 | 2016-04-19 | 2019-03-04 |
| Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF) Nintedanib, Pirfenidone - Idiopathic Pulmonary Fibrosis | Phase 4 | Completed | Hoffmann-La Roche | 89 | 2016-01-14 | 2018-06-13 |
| Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF Nintedanib, Pirfenidone - Idiopathic Pulmonary Fibrosis | Phase 4 | Completed | Boehringer Ingelheim | 105 | 2015-10-16 | 2018-02-13 |
| Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Exercise Performance Moderate altitude sojourn, Low altitude sojourn, Oxygen - Precapillary Pulmonary Hypertension, Interstitial Lung Disease | Phase 4 | Completed | University of Zurich | 30 | 2014-05-01 | 2021-10-07 |
| Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Breathing and Sleep Moderate altitude sojourn, Low altitude sojourn, Oxygen - Precapillary Pulmonary Hypertension, Interstitial Lung Disease | Phase 4 | Unknown | University of Zurich | 50 | 2014-05-01 | 2020-02-06 |
| Novartis Everolimus Transition Everolimus, Standard of Care - Graft Dysfunction, Interstitial Fibrosis | Phase 4 | Completed | Medical University of South Carolina | 60 | 2014-02-01 | 2018-08-08 |
| The Effects of Omega-3 Fatty Acids in Renal Transplantation Omega-3 fatty acids, Placebo - Disorder Related to Renal Transplantation | Phase 4 | Completed | Oslo University Hospital | 132 | 2013-11-01 | 2015-12-08 |
| Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Sildenafil - Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis | Phase 4 | Unknown | Rabin Medical Center | 60 | 2011-09-01 | 2012-11-15 |
| Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Ex vivo lung transplantation - Respiratory Tract Diseases | Phase 4 | Unknown | InCor Heart Institute | 20 | 2011-08-01 | 2011-05-12 |
| 68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis 68Ga-DOTA-NOC PET/CT - Idiopathic Pulmonary Fibrosis | Phase 4 | Terminated | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 29 | 2009-02-01 | 2015-01-27 |
| Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study Bosentan, Placebo - Pulmonary Hypertension, Interstitial Lung Disease | Phase 4 | Unknown | Royal Brompton & Harefield NHS Foundation Trust | 48 | 2008-04-01 | 2008-03-17 |
Showing 20 of 24. Sign in to see all of them.
Idiopathic Pulmonary Fibrosis (12) · Lung Diseases, Interstitial (7) · Hypertension, Pulmonary (4) · COVID-19 (2) · Pulmonary Arterial Hypertension (2) · Pulmonary Disease, Chronic Obstructive (2) · Alveolitis, Extrinsic Allergic (1) · Cicatrix (1) · Cough (1) · Cystic Fibrosis (1) · Disease Progression (1) · Fibrosis (1) · Inflammation (1) · Kidney Failure, Chronic (1)
Lung Diseases (24) · Respiratory Tract Diseases (23) · Lung Diseases, Interstitial (17) · Pathologic Processes (14) · Pathological Conditions, Signs and Symptoms (14) · Fibrosis (11) · Cardiovascular Diseases (4) · Disease Attributes (4) · Hypertension (4) · Vascular Diseases (4) · Chronic Disease (3) · Coronaviridae Infections (2) · Coronavirus Infections (2) · Female Urogenital Diseases (2)
nintedanib (7) · pirfenidone (5) · Bosentan (2) · Oxygen (2) · Sildenafil Citrate (2) · Sirolimus (2) · WW Domain-Containing Oxidoreductase (2) · Colchicine (1) · Cyclosporine (1) · Daclizumab (1) · Everolimus (1) · Fatty Acids, Omega-3 (1) · Gabapentin (1) · Olive Oil (1) · Omacor (1)
Boehringer Ingelheim (5) · University of Zurich (2) · ClinAmygate (1) · Hoffmann-La Roche (1) · Hospices Civils de Lyon (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Icahn School of Medicine at Mount Sinai (1) · InCor Heart Institute (1) · Medical University of South Carolina (1) · Oslo University Hospital (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Rabin Medical Center (1) · Rajan Saggar (1) · Royal Brompton & Harefield NHS Foundation Trust (1) · University Hospital, Antwerp (1)
United States (9) · France (4) · Germany (4) · Canada (3) · Italy (3) · United Kingdom (3) · Belgium (2) · Netherlands (2) · Spain (2) · Switzerland (2) · Australia (1) · Brazil (1) · Czechia (1) · Denmark (1) · Egypt (1)
Konrad E Bloch, MD (2) · Rajan Saggar, MD (2) · Athol U Wells, MD FRCP FRCR (1) · Brendan Madden, MD MSc FRCP (1) · David Taber (1) · Emad Issak (1) · Fabio B Jatene, PhD (1) · Ivar A Eide, MD (1) · Jean-Louis Bosmans, M.D. Ph.D. (1) · Luke Howard, DPhil MRCP (1) · Maria Padilla, MD (1) · Mordechai R Kramer, M.D (1) · Robert P Baughman, MD (1)
PMID 10221490, PMID 10798738, PMID 12438948, PMID 12761269, PMID 21078794, PMID 24937643, PMID 28889759, PMID 29946005, PMID 30125457, PMID 30167310, PMID 31326319, PMID 31365151, PMID 33419890, PMID 33902584, PMID 34658014, PMID 34939013, PMID 40216412
2015 (4), 2004 (1), 2019 (1)